300 related articles for article (PubMed ID: 36834851)
1. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.
Gabbia D; De Martin S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834851
[TBL] [Abstract][Full Text] [Related]
2. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
3. Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma.
Franses JW; Lim M; Burgoyne AM; Mody K; Lennerz J; Chang J; Imperial R; Dybel SN; Dinh TM; Masannat J; Weipert CM; Hsiehchen D
Oncologist; 2022 Nov; 27(11):e908-e911. PubMed ID: 36103364
[TBL] [Abstract][Full Text] [Related]
4. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
Front Immunol; 2022; 13():861525. PubMed ID: 35355983
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
Lin ZF; Qin LX; Chen JH
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
[TBL] [Abstract][Full Text] [Related]
6. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
7. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.
Lei J; Zhang D; Yao C; Ding S; Lu Z
Cancer Control; 2020; 27(1):1073274820977114. PubMed ID: 33269615
[TBL] [Abstract][Full Text] [Related]
8. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma.
Muhammed A; D'Alessio A; Enica A; Talbot T; Fulgenzi CAM; Nteliopoulos G; Goldin RD; Cortellini A; Pinato DJ
Expert Rev Mol Diagn; 2022 Mar; 22(3):253-264. PubMed ID: 35236211
[TBL] [Abstract][Full Text] [Related]
9. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
[TBL] [Abstract][Full Text] [Related]
13. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
15. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
16. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
19. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.
Xie C; Wu H; Pan T; Zheng X; Yang X; Zhang G; Lian Y; Lin J; Peng L
Aging (Albany NY); 2021 Mar; 13(6):8563-8587. PubMed ID: 33714200
[TBL] [Abstract][Full Text] [Related]
20. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
